NEW YORK, November 16, 2018 /PRNewswire/ --
According to data compiled by Mordor Intelligence, the Hospital Acquired Infection Control Market is expected to reach
USD 33.78 Billion by 2021 and is growing at a CAGR of 8.3% during the forecasted. The market being
driven by the demand to control spread of infections within a hospital environment, primarily driven by pathogen spread
infections. Other factors such as awareness with devices and cost effective drugs are also driving the market. Due to poor
conditions within a hospital or a patient's weak immune system can cause infections to spread throughout the facility. Infections
are usually treated by antibiotics, eating diets and natural healing, but the use of infection control medical devices can
potentially prevent the infection before it occurs. PCT Ltd. (OTC: PCTL), Rigel Pharmaceuticals, Inc.
(NASDAQ: RIGL), Achaogen, Inc. (NASDAQ: AKAO), Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), SCYNEXIS, Inc. (NASDAQ: SCYX)
Infections caused on site at facilities has become a growing concern, which is why the market is developing and expanding upon
medical equipment. The use of sterilized and disinfected medical equipment can help further prevent infections from spreading.
New technology advancements are helping with detection, tracking, isolation and treatment. "As infection prevention challenges
evolve-such as emerging infectious organisms and resistance-healthcare organizations must focus on preventing hospital-acquired
infections and ensuring better patient outcomes." said Lena Browning MHA, BSN, RN at Compass Clinical Consulting, "To achieve
these goals, Infection Prevention professionals must be involved in all decisions affecting the delivery of patient care.
Healthcare is ever-changing, and innovative approaches are critical as we look to the future of infection prevention."
PCT Ltd. (OTC: PCTL) announced breaking news last week that it, "has reached significant company milestones through its
wholly-owned operating subsidiary Paradigm Convergence Technologies Corporation (PCT Corp.). PCT Corp. has successfully
completed two Beta Site trials and installations at major healthcare facilities, which have been converted into long-term
agreements for its Annihilyzer® Infection Control Systems. PCT Corp. has also established agreements with several Manufacturing
Representatives for geographical territories in the healthcare market. With these milestones achieved, PCT Corp. has commenced
the full-scale marketing launch of its hospital infection control systems.
PCT LTD announced today that Jody Read, current Chief Operating Officer, was promoted to Chief
Executive Officer of PCT LTD and PCT Corp. Mr. Read will continue his duties as COO until it is determined that the position
needs to be filled by additional personnel. Gary Grieco, PCT LTD's current CEO, will continue as
Chairman of the Board of PCT LTD and will focus his attention on setting the course for the company and overseeing the Board.
Since 2014, Gary Grieco in his prior role as PCT LTD's CEO, has successfully built and secured
funding for PCT Corp., as a startup company. He acquired and developed under his leadership its patented, proprietary
technologies and directed the development of PCT Corp.'s products to the point in which PCT Corp. now has proof of concept and
commercial entry in its target markets.
Read joined PCT Corp. two years ago after successfully founding and managing Customer Service Associates, Inc. (CSA) for 18
years, a $44 Million dollar a year sales and support organization for the healthcare market with
over 350 employees providing equipment and services for the largest OEM's in healthcare. He has over 33 years of medical industry
background working for and with the largest manufacturers in the medical equipment business. Read's skills in management,
organization, sales, service and support will provide PCT with the leadership required to move PCT Corp. into the defined markets
PCT has initially targeted.
Gary Grieco stated, "Jody has proven himself over the past two years to be a great team leader
and his expertise in business management and healthcare equipment technologies will take PCTL and PCT Corp. to the next levels of
growth and profitability. I look forward to working with Jody and the entire PCT Team to drive PCT's growth."
About PCT LTD - PCT LTD ("PCTL") focuses its business on acquiring, developing and providing sustainable, environmentally safe
disinfecting and tracking technologies products. The company acquires and holds rights to innovative products and technologies,
which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp).
Currently trading on OTC, "PCTL" aspires to and is actively engaged in preparations for up-listing its common stock to a national
securities exchange. The Company established entry into its target markets with commercially-viable products and now prepares to
gain market share. PCT Corp's business mission is to profitably provide state-of-the-art Electro-Chemical Activation equipment,
disinfecting fluid solutions and PCT Corp's patented tracking system to hospitals and other facilities for the documentable
remediation of Hospital Acquired Infections (HAI's) from organisms such as Clostridium difficile (C. diff.), MRSA, VRE, CRE,
Klebsiella pneumoniae, and Pseudomonas, as well as to sell ECA fluid solutions to agricultural markets for the remediation,
control and suppression of microbial contamination and disease of certain commercial crops. The Company's primary fluid solution,
branded Hydrolyte®, is an EPA registered "hospital-level" disinfectant effective against common healthcare pathogens such as
Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, Candida albicans, and more; food processing bacteria
including E. coli, Listeria, and Salmonella; and organisms of veterinarian concern such as parvovirus, distemper and Bordetella.
PCT Corp.'s proprietary equipment product line includes: 1) PCT Hydrolyte® Generators, 2) PCT Annihilyzer® Infection Control
Systems, and 3) SurvivaLyte® equipment. The Hydrolyte® Generators produce large volumes of electrolyzed water for the
agriculture, oil and gas, and fluid distribution markets. The Annihilyzer® Infection Control Systems, which boast patented RFID
material tracking technology, Electrostatic Smart Applicators, on-site automated ECA generators, and Green Seal standards
containing stringent performance, health, and sustainability criteria, are ideal for hospitals and healthcare facilities. The
SurvivaLyte® unit is a portable, small volume generator with applications such as disaster recovery, emergency preparedness,
remote on-site needs, farm and ranch, and personal use. PCT Corp's unique patented systems and human-safe products provide
next-generation cleaning, sanitizing, disinfecting and decontaminating fluid solutions to the ever-present problems of microbial
infection and infestation."
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), is a biotechnology company dedicated to discovering, developing and
providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders,
cancer and rare diseases. Rigel Pharmaceuticals, Inc. recently announced that it had entered into an exclusive license and supply
agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") to develop and commercialize TAVALISSE™ in all current and potential
indications in Japan, China, Taiwan and the Republic of Korea. Kissei is a Japan-based pharmaceutical
company addressing patients' unmet medical needs through its research, development and commercialization efforts, as well as
through collaborations with partners. TAVALISSE is commercially available in the U.S. for the treatment of thrombocytopenia in
adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. "Kissei
is a leading Japanese pharmaceutical company with significant development experience and a track record of commercial success in
Asian markets. Their commitment to develop TAVALISSE in ITP, and potential future indications in these territories, makes Kissei
an optimal partner as we seek to expand the global market opportunity for this important new therapeutic," said Raul Rodriguez, President and Chief Executive Officer of Rigel. "This agreement demonstrates our approach to
entering strategic markets outside of the U.S. and emphasizes the unmet need that exists for chronic ITP, among other rare blood
disorders."
Achaogen, Inc. (NASDAQ: AKAO) is a biopharmaceutical company passionately committed to the discovery, development,
and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen, Inc. recently announced
the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for plazomicin. The Company
is seeking approval for the following indications: Complicated urinary tract infections (cUTI), including pyelonephritis
Bloodstream infections (BSI) due to certain Enterobacteriaceae and; Infections due to Enterobacteriaceae in adult patients with
limited treatment options. "Our mission is to bring much-needed antibiotics to patients globally and, with this MAA submission,
we are one step closer to that goal," said Blake Wise, Achaogen's Chief Executive Officer. "We
look forward to the acceptance of this application and the potential to bring a new treatment option to EU patients and
healthcare professionals who face the daily challenge of treating recurrent and resistant gram-negative infections."
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) is a biopharmaceutical company using its proprietary chemistry
technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of
the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for
Disease Control and Prevention. Tetraphase Pharmaceuticals, Inc. recently announced data from two post-hoc analyses of pooled
data from two Phase 3 IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) studies of XERAVA in patients
with complicated intra-abdominal infections (cIAI). "Treatment failure risk can increase in certain subgroups with cIAI,
including patients who are obese, and those with altered renal function," said Larry Tsai, M.D.,
Chief Medical Officer of Tetraphase. "Obesity may put patients at higher risk due to altered pharmacokinetics and comorbidities,
while renal function can be highly dynamic in patients with serious infections, which can result in significant over- or
under-dosing of antibiotics."
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients
suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies.
SCYNEXIS, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease
Product (QIDP) and Fast Track designations for the oral formulation of SCY-078, SCYNEXIS's novel oral and intravenous antifungal
agent, for the treatment of vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC. Additionally, SCYNEXIS today
announced it has completed enrollment in the Phase 2b, dose-finding study of oral SCY-078 for the
treatment of VVC (the DOVE study), with release of top-line data expected by July 2018. "These
designations from the FDA for the treatment of VVC and prevention of recurrent VVC highlight the significant unmet needs faced by
women suffering from these widespread infections," said Marco Taglietti, M.D., President and Chief
Executive Officer of SCYNEXIS. "We believe SCY-078 will provide a beneficial treatment option for healthcare providers and women
not satisfied with existing therapies. Moreover, we can now make use of the QIDP and Fast Track designations across all current
SCY-078 development programs, including VVC, invasive candidiasis and invasive aspergillosis."
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial
news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news
media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles
posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and
therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete.
FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along
with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias
commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only
aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pct ltd.
financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand
dollars by paradigm convergence. Our fees may be either a flat cash sum or negotiated number of securities of the
companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a
portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will
always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not
undertake to update any of the information on the editorial or Site or continue to post information about any companies the
information contained herein is not intended to be used as the basis for investment decisions and should not be considered as
investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any
security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions
expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own
independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By
accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may
be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to
purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any
investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a
particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation
needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment
decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are
subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness
are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.
For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
.
SOURCE FinancialBuzz.com